



# LUND UNIVERSITY

## Vitamin K: Nutrition, Metabolism and Current Evidence from Clinical Trials.

Dahlberg, Sofia; Nilsson, Caroline; KANDER, THOMAS; Schött, Ulf

*Published in:*

Nutrition and Metabolism: An Open Access

*DOI:*

[10.29011/NMOA-101/100001](https://doi.org/10.29011/NMOA-101/100001)

2018

*Document Version:*

Publisher's PDF, also known as Version of record

[Link to publication](#)

*Citation for published version (APA):*

Dahlberg, S., Nilsson, C., KANDER, THOMAS., & Schött, U. (2018). Vitamin K: Nutrition, Metabolism and Current Evidence from Clinical Trials. *Nutrition and Metabolism: An Open Access*, 1-13. Article NMOA-101. <https://doi.org/10.29011/NMOA-101/100001>

*Total number of authors:*

4

### General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00



# Vitamin K: Nutrition, Metabolism and Current Evidence from Clinical Trials

Sofia Dahlberg<sup>1</sup>, Caroline Ulfsdotter Nilsson<sup>1,2</sup>, Thomas Kander<sup>1,2</sup>, Ulf Schott<sup>1,2\*</sup>

<sup>1</sup>Department of Anaesthesia and Intensive Care, Institution of Clinical Science Lund, Medical Faculty, Lund, Sweden

<sup>2</sup>Department of Anaesthesia and Intensive Care, Skåne University Hospital Lund, Lund, Sweden

**\*Correspondence author:** Ulf Schott, Department of Anesthesia and Intensive Care, Skåne University Hospital, Lund, Sweden and Institution of Clinical Science Lund, Medical faculty, Lund University, Sweden. Tel: +4646171319; Fax: +4646176050; Email:ulf.schott@skane.se

**Citation:** Dahlberg S, Nilsson CU, Kander T, Schott U (2018) Vitamin K: Nutrition, Metabolism and Current Evidence from Clinical Trials. Nutr Metab Open Acc: NMOA-101. DOI:10.29011/NMOA-101/100001

**Received Date:** 11 April, 2018; **Accepted Date:** 23 April, 2018; **Published Date:** 01 May, 2018

## Abstract

During the past decades evidence that vitamin K is involved in areas extending far beyond hemostasis has accumulated. Several mechanisms of action involving both direct interaction via receptors such as the steroid and xenobiotic receptor and indirect via post-translational activation of Gla proteins have been proposed. The metabolism of vitamin K is complex and has large interspecies variation. Also, the vitamin K content in various foods and the recommended daily intake are not clearly specified. Notwithstanding, several clinical trials evaluating the effect of different vitamin K species on cardiovascular disease, osteoporosis, metabolic disease and cancer are ongoing or recently completed. The review attempts to summarize the source and metabolism of different forms of vitamin K, as well as give an overview of the current evidence from clinical trials.

**Keywords:** Atherosclerosis; Cancer; Diabetes; Growth Arrest Specific 6 Protein; Matrix Gla Protein; Osteocalcin; Vitamin K<sub>2</sub>


## Introduction

During the last two decades, the research focus of vitamin K has shifted from coagulation to a broader range of topics involving cardiovascular disease, osteoporosis, diabetes and cancer. Since its discovery in the 1930s vitamin K has been most recognized for its involvement in post-translational  $\gamma$ -carboxylation of hepatic clotting factors II, VII, IX and X as well as protein C, S and Z. In addition, several vitamin K dependent proteins originating from extra-hepatic tissues have been identified. These are collectively named Gla proteins, referring to the transformation of Glutamate (Glu) residues to  $\gamma$ -carboxyglutamic (Gla) during carboxylation upon which the protein adapts a tertiary structure able to bind calcium ions [1]. While the introduction of new oral anticoagulants may have diminished the research interest of vitamin K in hemostasis, new applications are emerging for vitamin K and the associated extra-hepatic Gla proteins. The most extensively researched Gla proteins are Matrix Gla Protein (MGP), Osteocalcin (OC), Growth Arrest Specific 6 protein (gas6) and Gla Rich Protein (GRP). MGP is a potent calcification inhibitor and high levels of desphospho-uncarboxylated MGP (dp-ucMGP)

has been correlated to increased vascular calcification score [2,3] and mortality [4] in at-risk populations. Similar to MGP, GRP is thought to prevent calcification in its carboxylated state [5]. OC is involved in bone metabolism [6] and gas6 has been implicated in proliferative and inflammatory signaling [7]. The activity of the aforementioned Gla proteins is dependent on their  $\gamma$ -carboxylation status. Therefore, an inadequate intake of vitamin K may result in suboptimal function of the Gla proteins. This is supported by large-scale studies demonstrating inverse associations between vitamin K intake and cancer [8] and cardiovascular disease [9]. The recommended daily intake of vitamin K is based on the amount needed to fully carboxylate hepatic coagulation proteins and does not take extra-hepatic Gla proteins into account. Furthermore, different forms of vitamin K seem to have different bioavailability for the extra-hepatic Gla proteins. Previous studies have demonstrated that substantial fractions of MGP and OC are uncarboxylated in healthy subjects [10], suggesting that vitamin K insufficiency might be more common than previously thought. The aim of this review is to summarize the source and metabolism of different forms of vitamin K, as well as give an overview of the current evidence from clinical trials investigating the efficacy of vitamin K supplementation on cardiovascular disease, diabetes, osteoporosis and cancer.

## Different Forms of Vitamin K

Vitamin K occurs naturally in two forms, vitamin K<sub>1</sub> (Phylloquinone) and vitamin K<sub>2</sub> (Menaquinone). Together with the other fat-soluble vitamins D, E and A, quinones belong to the large isoprenoid (terpenoid) family, which among others also comprise sterols and carotenoids [11]. All forms of vitamin K share a polar, hydrophilic 2-methyl-1,4-naphthoquinone ring structure (Menadiene, vitamin K<sub>3</sub>), which is accompanied by a hydrophobic side chain of varying length and saturation. Vitamin K<sub>1</sub> has a phytyl side chain attached to the naphthoquinone head and contains only one unsaturated bond. Vitamin K<sub>2</sub> is subdivided into menaquinone-n (MK-n) where n is the number of prenyl units in the isoprenoid side chain with repeating unsaturated bonds [12]. In addition, synthetic forms vitamin K<sub>3</sub>-K<sub>5</sub> exist. The molecular structure of the different forms of vitamin K is shown in (Figure 1).



**Figure 1:** Molecular structures of Vitamin K<sub>1</sub> and menaquinone-4 and -7.


For vertebrate's vitamin K is an essential micronutrient. Vitamin K<sub>1</sub> is synthesized by photosynthetic organisms and plays a vital role as electron carrier in leafy plants, which is the main dietary source of vitamin K<sub>1</sub> for humans [13]. Vitamin K<sub>2</sub> is produced by obligate and facultative anaerobic bacteria and occurs in animal livers and fermented foods such as cheese, curd and the Japanese specialty natto. Bacteria mainly synthesize long-chain vitamin K<sub>2</sub> (MK-7 – MK-13) using distinct pathways reviewed elsewhere [14]. MK-4 may be found in poultry and pork products. This is because animal feed often use synthetic derivative vitamin K<sub>3</sub> as a source of vitamin K [15], which is converted to MK-4 *in vivo*. The conversion of vitamin K<sub>1</sub> and K<sub>3</sub> to MK-4 is described more in detail below. Furthermore, MK-4 is a ligand to the steroid

and xenobiotic receptor (SXR) through which it can affect gene transcription [16]. In general, tissue stores of vitamin K are low. Hepatic stores comprise almost exclusively of long-chain vitamin K<sub>2</sub> and the ratio of vitamin K<sub>1</sub> being only around 10%. In extra-hepatic tissues, especially in the brain, kidney and pancreas, MK-4 is the main form [17].

Already in the late 1950s, animal experiments revealed that animals fed vitamin K<sub>3</sub> or vitamin K<sub>1</sub> demonstrated increased levels of MK-4 in several organs [18]. When vitamin K<sub>1</sub> was administered parentally to pigeons the increase of MK-4 was not seen. In a study from 2006, increased urinary excretion of vitamin K<sub>3</sub> was seen after vitamin K<sub>1</sub> or MK-4 intake in healthy male volunteers [19]. The authors concluded that part of the MK-4 tissue stores derives from uptake and prenylation of circulating vitamin K<sub>3</sub>. *In vivo* conversion of vitamin K<sub>1</sub> or vitamin K<sub>3</sub> to vitamin K<sub>2</sub> form MK-4 was demonstrated in mice brain when administered orally or enterally [20]. When administered intravenously or intrathecally only vitamin K<sub>3</sub> produced a low increase of cerebral MK-4 concentration. However, in cerebral slice cultures as well as primary cultures both vitamin K<sub>1</sub> and vitamin K<sub>3</sub> were converted to MK-4. This implies that the conversion from vitamin K<sub>1</sub> to MK-4 may happen through two routes, the first being side-chain removal that happens during intestinal absorption and vitamin K<sub>3</sub> is then prenylated to form MK-4 in the target tissue. The second route is both side chain removal and prenylation taking place at tissue level. The same research group identified UbiA prenyltransferase containing 1 (UBIAD1), a human homologue of *Escheria coli* prenyltransferase MenA, as the biosynthetic enzyme responsible for MK-4 synthesis [21]. As UBIAD1 was able to convert both vitamin K<sub>1</sub> and vitamin K<sub>3</sub> to MK-4, authors postulated that UBIAD1 may cleave the side chain to form vitamin K<sub>3</sub> which is then prenylated by geranylgeranyl pyrophosphate to form MK-4. Inhibition of UBIAD1 by drugs such as statins have been postulated to contribute to vascular calcification due to depletion of vascular vitamin K<sub>2</sub> levels [22].

## The Vitamin K Cycle

Since the discovery of vitamin K's role in post-translational gamma-carboxylation of proteins in the 1970s there has been extensive research surveying the reactions involved in the transformation from Glu to Gla. This resulted in the identification of the vitamin K cycle, which is a series of enzymatic modifications vitamin K undergoes in order to support in carboxylation (Figure 2).



**Figure 2:** An updated Vitamin K cycle. See text for abbreviations.

In the initial step, vitamin K is reduced by Vitamin K Reductase (VKR) to form Vitamin K Hydroquinone (KH<sub>2</sub>). KH<sub>2</sub> is then utilized by Gamma-Glutamyl Carboxylase (GGCX) which modifies glutamic acid residues to gamma-carboxy glutamic acid in Gla proteins. This reaction also requires presence of oxygen and carbon dioxide. GGCX recognizes its substrates through an amino acid sequence called the propeptide [23]. Despite comparatively high homology among the propeptides the affinity of GGCX for different Gla proteins varies significantly [24]. During the carboxylation process, KH<sub>2</sub> is oxidized to vitamin K<sub>2,3</sub>-epoxide (KO), from which vitamin K is regenerated by the enzyme Vitamin K Epoxide Reductase (VKOR) and re-enters the cycle. VKOR is the target of vitamin K antagonists such as warfarin [25]. The reducing equivalents necessary for the VKOR reaction require a redox partner. The donated electrons have been proposed to derive from Thioredoxin (Trx)-like Protein disulfide reductase (PDI) in the Endoplasmic Reticulum (ER) [26] as well as ER membrane-anchored Trx-like protein TMX [27]. Several factors are involved in the regulation of the vitamin K cycle. Among them, there is the endogenous ER chaperone protein calumenin which has been shown to function as a negative regulator by inhibiting GGCX and VKOR in rats [28]. *In vitro* studies using short interfering RNA (siRNA) silencing calumenin demonstrated a significant increase in functional FIX [29]. Similarly, *in vitro* animal experiments showed that overexpression of VKOR subunit vitamin K epoxide reductase complex subunit 1 (VKORC<sub>1</sub>) increased production of FIX [30].

## Gla Proteins

In 1974, the vitamin K dependent modification where glutamic acid residues are transformed to  $\gamma$ -carboxy-glutamic acid were first described in coagulation proteins [31]. Since then, several vitamin K dependent proteins have been identified and some of them have become subject to extensive research due to their reported involvement in various conditions. Among these proteins, there are OC, MGP, gas6 and GRP. Identified in the

1970s, OC was the first Gla protein discovered that originated from extra-hepatic tissues [32]. OC is mainly produced by osteoblasts and has been suggested to affect bone metabolism by regulating osteoblast activity and bone mineralization [6]. More recently, OC was unexpectedly reported to be involved in glucose metabolism after studies showing that OC-deficient animals demonstrated hyperglycemia, hypoinsulinemia and increased visceral fat as compared to wild type animals [33]. Further animal studies suggested that the uncarboxylated form of OC (ucOC) mediated the endocrine properties by interacting with the pancreatic  $\beta$ -cells through the G protein-coupled receptor class C group 6 member A (Gprc6a) receptor [34]. UcOC was also reported to affect male fertility via Gprc6a in mice. However, some controversy as to whether these results can be applied to humans exists. The current evidence is discussed more in depth in the section about studies on vitamin K supplementation.

MGP was identified in the 1980s from bovine bone matrix [35], and shortly thereafter MGP expression was demonstrated in endothelial cells, fibroblasts, chondrocytes and vascular smooth muscle cells (VSMC). The function of carboxylated MGP as a calcification inhibitor has been confirmed in several preclinical studies [36]. A recent observational study demonstrated that elevated plasma dp-ucMGP was associated with increased cardiovascular mortality [37]. The significance of MGP for vascular health and whether increased carboxylation of MGP could reduce the progression of arterial calcification in risk group populations is currently being investigated in several clinical trials [38]. Arterial calcification may be present in the intima as obstructing macrophage- and lipid-rich plaques or in the media leading to vessel stiffness. The process of calcification is thought to be regulated by VSMCs, which are plastic in nature and may differentiate into different phenotypes. The characteristics and specific drives for intimal and medial calcification have been reviewed elsewhere [39]. Accumulation of uncarboxylated MGP has been demonstrated in both intimal and medial calcification [40]. Gas6 is structurally similar to protein S and both function as ligands to the Tyro3, Axl and MerTK (TAM) receptor family. TAM receptors activate downstream signalling pathways involved in inflammation, hemostasis, cell cycle regulation and proliferation [41]. Previous studies have suggested that Gas6 is involved in the carcinogenesis [7], diabetes [42] and inflammation [43]. However, results conflict and no clear role has been established. In several studies the degree of  $\gamma$ -carboxylation was not considered. In its uncarboxylated state, Gas6 does not activate TAM receptors [44]. To date, no *in vivo* studies on humans investigating Gas6 carboxylation degree and how it responds to vitamin K supplementation exist. GRP is the most recently identified Gla protein. Previous studies suggest that GRP is involved in cardiovascular calcification, possibly functioning in a complex together with MGP and fetuin-A. Similar to MGP, the calcification inhibition is dependent on  $\gamma$ -carboxylation status [5].



Dietary Sources of Vitamin K

As mentioned above the main source of vitamin K<sub>1</sub> is leafy vegetables, which have been reported to contain 400-700 µg vitamin K<sub>1</sub> per 100 g, with the highest concentrations reported for the vegetables with the darkest green leaves [45]. In addition, vegetable oils provide an important contribution with concentrations ranging from 50-200 µg vitamin K<sub>1</sub> per 100 g. Principal sources of vitamin K<sub>2</sub> in the Western diet are fermented dairy products, with MK-9 and MK-8 being the predominating forms [46]. However, a wide intervariability in the vitamin K<sub>2</sub> content between the different dairy products have been demonstrated. Soft and blue cheese have very high concentrations which might be attributed to their lactic acid bacteria species. The Japanese soy dish natto contains very high levels of MK-7 due to its fermentation with *Bacillus subtilis*, which is also capable of synthesizing MK-7 in the intestines several days after ingestion. As this may result in unpredictable plasma levels of vitamin K, patients undergoing anticoagulant treatment with vitamin K antagonists (VKA) such as warfarin are strongly discouraged from eating natto. However, a study on healthy volunteers demonstrated only mild increases in plasma MK-7 with relatively stable levels up to 48 hours after ingestion when eating boiled natto, compared to markedly increased concentrations with regular natto, most likely since the boiling process eliminated the *Bacillus* species [47]. Another source of vitamin K<sub>2</sub>, in the form of MK-4, is pork and poultry products from animals supplemented with vitamin K<sub>3</sub>, which as described above can be converted to MK-4 *in vivo*. The dietary sources of different forms of vitamin K are summarized in Table 1.

In a study published in 2000, vitamin K<sub>1</sub> and K<sub>2</sub> contents of a large number of food items were analyzed [48]. Vitamin K<sub>1</sub> occurred most abundantly in kale, spinach and broccoli with concentration ranging from 156-817 µg per 100 grams. Vitamin K<sub>2</sub> was divided into MK-4 - MK-9. The highest MK-4 concentrations were found in goose liver paste (369 µg per 100 gram), goose leg (31 µg per 100 gram) and egg yolk (31.4 µg per 100 gram). MK-8 and MK-9 were mainly present in hard and soft cheeses as well as curd cheese (MK-9), with a peak concentration of 51.1 µg per 100 gram. MK-7 was found in unparallel concentrations in natto (998 µg per 100 gram), which also contained smaller amounts of vitamin K<sub>1</sub>, MK-5, MK-6 and MK-8. With the exception of natto, MK-5 and MK-6 were only found in very low concentrations. Another study analyzing vitamin K content in fresh and processed pork products found high concentrations of MK-10 (289-492 µg per 100 gram), as well as MK-4 concentrations ranging from 3 to 27 µg per 100 gram [49]. Authors speculated that these products might be important contributors to overall vitamin K intake and hepatic stores, but since no studies have investigated the bioavailability of MK-10 it is difficult to draw any conclusions on its effect on vitamin K status in extra-hepatic tissues.

Type of Vitamin K	Dietary source	Suggested effects from supplementation trials
Vitamin K <sub>1</sub> , phyloquinone	Leafy vegetables (e.g. kale, spinach, broccoli), vegetable oils	Increased insulin sensitivity in prediabetic women [50]. Decreased insulin resistance in nondiabetic adults [51].
Vitamin K <sub>2</sub> , Menaquinone (MK) MK-4	Pork and poultry products (e.g. goose liver paste, egg yolk).	Positive effects on bone health in osteoporotic subjects [52].
MK-7	Fermented foods (e.g. cheese, Japanese specialty natto)	Positive effects on cardiovascular health in renal transplant patients [53].
Vitamin K <sub>3</sub> , menadione	Synthetic form, used in animal feed.	Cytotoxic, may be used in cancer therapy[54,55].

Table 1: Different forms of Vitamin K.

Vitamin K in the Intestines

As the human gut flora contains bacterial species capable of vitamin K<sub>2</sub> synthesis, it was initially thought these contributed significantly to vitamin K status. This perception was supported by studies reporting antibiotics-induced hypoprothrombinaemia attributed to the elimination of intestinal bacteria [56]. However, a comprehensive review published in 1995 concluded that even though gut microbes provided some contribution to human vitamin K status, it was much less than previously thought. The majority of vitamin K<sub>2</sub> producing bacteria is present in the colon, where gall salts and pancreatic enzymes required for vitamin absorption are missing [57].

The Absorption and Transport of Vitamin K

Similar to other fat-soluble nutrients, vitamin K absorption in the intestines is dependent on pancreatic enzymes and gall salts to form micelles that enterocytes can take up. Previous studies suggest that the bioavailability of vitamin K varies significantly between different foods, for instance the availability from spinach was reported to be only 4% of that from the liquid formulation Konakion [58]. Other studies suggest that vitamin K<sub>1</sub> absorption is significantly greater after consumption of vegetable oil compared

to broccoli [59]. Following intestinal absorption, vitamin K is incorporated into chylomicrons and enters the lymphatic circulation. Chylomicrons are degraded by endothelial lipoprotein lipases to chylomicron remnants, which together with very low-density lipoproteins (VLDL) are referred to as triglyceride-rich lipoproteins (TRL). A smaller but significant fraction of Vitamin K is also transported with low density lipoproteins (LDL) and high-density lipoproteins (HDL). Using deuterium-labeled greens, studies have shown that the plasma vitamin K<sub>1</sub> concentration peaks approximately 6 to 9 hours after ingestion and baseline levels are restored within 24 hours [60]. Vitamin K<sub>2</sub> shows large variation between the subspecies in terms of bioavailability and lipoprotein transport. MK-4 is rapidly cleared from the circulation and distributed equally between TRL, LDL and HDL whereas MK-9 was initially only found in TRL and later in LDL where it remained for up to 48 hours [61]. MK-7 has been shown to be present in circulation for up to 96 hours, suggesting it has higher availability for both hepatic and extra-hepatic Gla proteins [62]. Another factor suggested to impact vitamin K status is polymorphisms in Apolipoprotein E (ApoE), which is a LDL component and related to cellular uptake of lipoproteins. Among the three human alleles E2, E3 and E4, studies have shown that ApoE4 carriers clear vitamin K from the circulation more efficiently which results in lower plasma levels of vitamin K [63]. However, another recent study reported that the ApoE2 allele was associated with markedly decreased urinary Gla excretion indicative of a poor vitamin K status [64].

## Vitamin K Deficiency

In the adult population, hepatic vitamin K deficiency resulting in impaired coagulation is extremely rare. However, studies on perioperative changes in uncarboxylated prothrombin (Proteins induced by vitamin K absence factor II, PIVKA-II) have demonstrated increased PIVKA-II levels preoperatively without bleeding diathesis, suggesting that subclinical hepatic deficiency might be widespread [65,66]. Furthermore, studies on healthy subjects imply a suboptimal vitamin K status in extrahepatic tissues, which is more pronounced in children and adults above 40 years old [67]. Populations at-risk for developing vitamin K deficiency include patients with impaired intestinal absorption [68,69], and patients with chronic kidney disease as it was recently demonstrated that experimentally induced uremia in rats decreases GGCX activity in the liver and kidneys [70]. Substantial evidence from several independent studies suggest that vitamin K deficiency is common in patients with Chronic Kidney Disease (CKD), both in early stages and in those receiving dialysis [71]. CKD patients are also especially at-risk for cardiovascular disease and demonstrate increased vascular calcification. Results from intervention trials with vitamin K in CKD patients are discussed in the section about vitamin K supplementation. In 1996, a study on the dihydro-vitamin

K<sub>1</sub> content in various foods was published. Dihydro-vitamin K<sub>1</sub> is a vitamin K<sub>1</sub> derivative which is generated from hydrogenation of vegetable oils and thus occurs in fast foods such as French fries and chicken nuggets. This study demonstrated that in some age groups in the American population dihydro-vitamin K<sub>1</sub> accounts for roughly 30% of the total vitamin K intake [72]. Animal studies have shown that dihydro-vitamin K<sub>1</sub> is able to function as a cofactor in gamma-carboxylation, but it is not converted to MK-4 in extra-hepatic tissues [73,74]. Therefore, groups who consume less vegetables and more processed food, such as socioeconomic disadvantaged groups [75], might be prone to develop extra-hepatic vitamin K deficiency. Another population at risk for developing vitamin K deficiency are neonates as the transplacental passage of vitamin K is limited [76]. A coagulopathy with all the attributes of Vitamin K deficiency bleeding (VKDB) was first described in 1894. Neonatal vitamin K deficiency can be classified as early, classical and late [77]. Early VKDB presents within the first 24 hours of life and is often associated with maternal drugs such as warfarin and anticonvulsants. Classical VKDB manifests during the first week of life, typically between day 2 and 3 due to a natural dip in prothrombin activity [78]. In previous studies, infant vitamin K status has been related to the intake of milk [79], stressing the importance of adequate nutrition. Late VKDB presents after the first week with a peak incidence between 3 and 8 weeks. Late VKDB tend to be more severe and is associated with a high incidence of intracranial hemorrhage. The late form of VKDB may be idiopathic or secondary to insufficient breast feeding or underlying diseases such as biliary atresia or  $\alpha_1$ -antitrypsin deficiency [77]. In the 1950s it was demonstrated that antepartum administration of vitamin K to mothers decreased the incidence of neonatal hemorrhage [80]. Initially, water-soluble vitamin K<sub>3</sub> (e.g. Synkavit) was used as prophylaxis but it had rare albeit serious side effects in the form of hematological toxicities such as hemolytic anemia and kernicterus, probably related to erythrocyte glutathione metabolism [81,82]. Therefore, intramuscular administration of vitamin K<sub>1</sub> is the most commonly used prophylactic agent, although vitamin K<sub>3</sub> is still used in developing countries [83,84]. In 1990, a publication claiming intramuscular vitamin K administration to neonates was associated with increased risk of childhood leukemia gained widespread attention [85]. However, several studies since found no evidence for this association [86,87]. Lastly, anticoagulant treatment with VKAs impairs recycling of vitamin K and increases the risk of suboptimal carboxylation of Gla proteins. This is in line with several studies demonstrating negative effects of warfarin treatment of cardiovascular health [88,89].

## Recommended Daily intake and Supplementation

Initially, dietary recommendations were based on the amount of vitamin K needed to correct bleeding diathesis in elderly hospitalized men, which was estimated to 0.03  $\mu$ g per kg

body weight daily [90]. This has been revised multiple times and currently global guidelines vary between 50 to 120 µg per day [91] for adults. For infants aged 0-6 months a reference daily intake of 10 µg has been suggested, and is satisfied either by a single intramuscular dose of 1 mg vitamin K<sub>1</sub> at birth or repeated oral doses during the first 6-8 weeks [92]. These recommendations are based on vitamin K<sub>1</sub>, which is the main form in Western diets. However, studies suggest that an intake between 200 to 500 µg per day may be needed to ensure optimal carboxylation of the extra-hepatic Gla proteins [93]. Vitamin K<sub>2</sub> has better bioavailability for extra-hepatic Gla proteins. When administered daily, 25 µg MK-7 daily has been shown to be more efficacious than 100 µg Vitamin K<sub>1</sub>, and 50 µg MK-7 has been suggested to interfere with anticoagulant therapy [62]. Currently, there are no dietary reference values for vitamin K<sub>2</sub>, and challenges in establishing reference limits include lack of accurate data on food content and intake of different MK species [94]. A complicating factor in establishing adequate reference intervals for vitamin K intake is the lack of a gold standard method for assessing vitamin K status. Measuring vitamin K in plasma is difficult due to the low circulating levels and interference from triglycerides [95]. However, in recent studies determination of vitamin K<sub>1</sub>, MK-4 and MK-7 were performed using liquid chromatography tandem mass spectrometry [96]. Another approach is to measure the carboxylation degree of Gla proteins. In a previous review, authors proposed a combination of biomarkers as this might better reflect vitamin K status [97]. Several vitamin K supplements are available today. However, there is a significant cost difference between the different vitamin K forms. Whereas supplementation with vitamin K<sub>1</sub> has been estimated to cost \$199.8, vitamin K<sub>2</sub> yields costs estimated to be \$865.2 annually [98]. The different strategies to produce MK species include liquid and solid state fermentation, and research on how to improve efficacy and reduce cost in MK production is ongoing [99].

## Studies on Vitamin K Supplementation

### Cardiovascular Disease

The discovery of MGP and the accumulating evidence from preclinical studies that improved vitamin K status may prevent progression of or even reduce existing vascular calcification have motivated several clinical trials.

In 2004, a randomized case-control study showed that postmenopausal women who were supplemented with vitamin K<sub>1</sub> during three years demonstrated unchanged elastic properties of the common carotid artery whereas these properties were decreased in the other study groups [100]. In 2009, the results of a 3-year double-blind Randomized Controlled Trial (RCT) where 388 healthy older adults were given a daily multivitamin with or without 500 µg vitamin K<sub>1</sub> were published. In unadjusted

results there were no differences in the progression of Coronary Artery Calcification (CAC) between the groups, but in secondary analyzes restricted to participants who were > 85% adherent, the vitamin K<sub>1</sub> supplemented group has 6% less progression compared to controls [101]. However, a recently published RCT on 80 older adults with established vascular disease who were given 100 µg MK-7 or placebo daily during six months failed to demonstrate any significant improvement of markers of vascular health. A modest non-significant improvement of pulse-wave velocity was seen in the vitamin K supplemented group. Authors speculated that the lack of significant effects could be related to insufficient doses or too short observation time [102]. Currently, trials evaluating the efficacy of vitamin K<sub>1</sub> supplements in reducing progression of vascular calcification in patients with severe kidney disease are ongoing. In the VitaVasK trial 348 hemodialysis patients are randomized to receive either 5 mg of vitamin K<sub>1</sub> thrice weekly or stay on standard care. Using Multi-Slice Computed Tomography (MSCT) thoracic aortic and coronary artery calcification will be evaluated after 12 and 18 months and compared to baseline scans [103]. The iPACK-HD Randomized Controlled Trial (RCT) has a similar aim and enrolls end stage kidney disease patients who receive either 10 mg vitamin K<sub>1</sub> or placebo three times weekly after dialysis. High-Resolution Computed Tomography (HRCT) is performed at baseline and after 12 months to evaluate progression of CAC [104]. In 2014, a randomized, single-blinded dose-finding study evaluated the effect of MK-7 on dp-ucMGP. Two hundred hemodialysis patients received 360, 720 or 1080 µg MK-7 thrice weekly during 8 weeks. MK-7 dose-dependently reduced circulating levels of dp-ucMGP [105]. Similar results were repeated by another study including 50 hemodialysis patients who received 360 µg MK-7 daily during four weeks, with a resulting drop of dp-ucMGP levels of 86% [106]. This has motivated further research with larger study populations and increased trial length. A three-year double-blind RCT investigating the effect of daily supplementation with 180 µg MK-7 in healthy postmenopausal women demonstrated decreased arterial stiffness in the supplemented group [107]. Currently, several clinical trials investigating the effect of vitamin K<sub>2</sub> (MK-7) on progression of vascular calcification are ongoing. Among them, there is the vitaK-CAC trial in which patients with pre-existing CAC will be randomized to receive 360 µg MK-7 or placebo during 24 months after which vascular health will be evaluated to determine whether MK-7 slows down the rate of progression [108]. As mentioned before, patients suffering from CKD are of particular interest as several studies suggest that they have a high prevalence of both vitamin K deficiency and cardiovascular disease. Some of the aforementioned clinical trials specifically include subjects with severe kidney disease or dialysis. In a randomized trial including 53 long-term hemodialysis patients receiving placebo or MK-7 (doses 45 µg, 135 µg or 360 µg) daily for 6 weeks a dose- and



time-dependent reduction of dp-ucMGP, ucOC and PIVKA-II was demonstrated [109]. In the recently published KING trial, comprising 60 renal transplant recipients supplemented with 360 µg MK-7 daily for 8 weeks, supplementation resulted in decreased dp-ucMGP levels and a 14.2 % reduction in mean carotid-femoral pulse wave velocity [53].

## Bone Disease

Due to the aforementioned relationship between Vitamin K and bone health several clinical trials have evaluated the effect of vitamin K supplementation on bone turnover. In 2006 a systematic review comprising 13 studies concluded that both vitamin K<sub>1</sub> and vitamin K<sub>2</sub> had a protective effect by reducing bone loss as well as a strong decreasing effect of vitamin K<sub>2</sub> on bone fracture incident rate in Japanese patients [110]. Another review published in 2009 included seven RCTs where postmenopausal women were supplemented with vitamin K<sub>1</sub> or K<sub>2</sub> for at least two years. Supplementation with high doses (5 mg vitamin K<sub>1</sub> and 45 mg vitamin K<sub>2</sub>, MK-4 daily) consistently decreased ucOC levels and albeit bone resorption markers were unaffected the bone strength measured as femoral neck width was improved and fracture incidence was reduced [111]. The modest effect on bone resorption was explained by the fact that OC and MK-4-mediated activation of SXR rather stimulates osteoblast differentiation. However, the largest RCT included in this review, comprising around 4000 women with osteoporosis supplemented with 45 mg MK-4, only demonstrated beneficial effects in women with advanced osteoporosis. The cumulative 2-year incident rate was lower among supplemented subjects but the difference was not statistically significant. However, vitamin K-substituted subjects experienced improvement of several activities of daily living (ADL) parameters during the first 12 months of the study compared to controls [112]. In 2015 a systematic review of nineteen RCTs enrolling 6759 participants was performed. Results showed that medium and long-term treatment with vitamin K<sub>2</sub> improved vertebral bone mineral density (BMD) in osteoporotic women, but did not affect BMD in the non-osteoporotic subgroup. Fracture incidence was decreased in the vitamin K<sub>2</sub>-treated subjects after sensitivity analysis excluded one study, however the remaining studies had limiting factors such as small sample sizes and lack of critical data such as fracture incidence rate. Nevertheless, authors concluded that osteoporotic women had encouraging results, and that vitamin K<sub>2</sub> may reduce fracture incidence [52]. In summary, many RCTs evaluating the efficacy of vitamin K on bone loss have been performed. However, due to different limitations such as small study samples, it is difficult to confirm the role of vitamin K and to what extent it may affect bone pathology. Currently, studies on concurrent therapy with vitamin K<sub>2</sub> and bisphosphonates are ongoing comprising roughly 1000 study subjects in each group [113].

## Cancer

Vitamin K has gained attention in cancer research after several preclinical studies have shown anti-tumour responses produced by different vitamin K forms [114]. Also, large population studies have demonstrated inverse correlations between vitamin K intake and cancer incidence and mortality [8,115]. Few clinical trials exist, and have mainly focused on whether MK-4 supplementation prevents recurrence of hepatocellular carcinoma (HCC) after curative resection. A systematic review analyzing these trials found no beneficial effect on overall survival or improved tumour recurrence with MK-4 [116]. Vitamin K<sub>3</sub> has the ability to generate ROS, therefore it has been of interest in cancer research [117]. Vitamin K<sub>3</sub> administration to patients with advanced HCC yielded reduction of tumour size in 17% of the patient population. These patients also had increased mean survival time, even though overall mortality remained unchanged [54]. In 2008 a clinical trial comprising 17 patients suffering from therapy-resistant prostate cancer demonstrated significant decrease in prostate specific antigen (PSA) increase rate after receiving concomitant vitamin K<sub>3</sub> and vitamin C treatment during 12 weeks. However, no decrease of absolute PSA was observed [55].

## Metabolic Disease

Not many large-scale studies on the effect of vitamin K on diabetes exist. In a prospective cohort study encompassing 38 094 Dutch men and women, dietary intake of both vitamin K<sub>1</sub> and vitamin K<sub>2</sub> was inversely associated with type 2 diabetes. Furthermore, vitamin K<sub>2</sub> intake was correlated to a favorable lipid profile and lower CRP levels [118]. Cross-sectional analyses from the PREDIMED study showed that dietary vitamin K<sub>1</sub> estimated from a food frequency questionnaire was associated with reduced risk of type 2 diabetes [119]. Data from the National Health and Nutrition Examination Survey (NHANES) study comprising 5800 US adults suggested that vitamin K<sub>1</sub> intake had a positive influence on the metabolic syndrome and that the highest quartile of intake was associated with significantly reduced risk of low HDL level, hypertriglyceridemia, and hyperglycemia compared to the lowest quartile [120]. Similarly, a high vitamin K<sub>2</sub> intake has been associated with lower occurrence of the metabolic syndrome in a 10-year follow-up study on adults [121].

Supplementation trials investigating the relationship between vitamin K and diabetes are scarce. In a study where prediabetic women were randomized to receive either 1000 µg Vitamin K<sub>1</sub> or placebo once daily during four weeks, the supplemented group demonstrated increased insulin sensitivity and glycemic status. However, insulin resistance was not affected [50]. Another study found that daily supplementation with 500 µg vitamin K<sub>1</sub> to older non-diabetic adults during three years, decreased insulin



resistance defined as the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) [51]. However, a meta-analysis published in 2017 comprising eight RCTs with a total of 1077 participants found no effect of vitamin K supplementation on insulin sensitivity. The authors suggested that larger, well-designed RCTs are needed to establish whether any association exists and if so determine its clinical relevance [122]. The relationships between OC and glucose homeostasis observed in animal studies have warranted several studies aiming to determine if the preclinical results can be extrapolated to humans. Variations of the gene bone gamma carboxyglutamate protein (BGLAP), which encodes OC, have been linked to alterations in body mass index (BMI) in an European population [123]. In 2015, several meta-analyses were published. Two of them looked specifically at type 2 diabetes and found that type 2 diabetes patients had significantly lower plasma levels of OC. Furthermore, an inverse association between OC levels and risk of developing type 2 diabetes were demonstrated in these studies [124,125]. Another meta-analysis showed inverse correlations between both total OC and ucOC with fasting plasma glucose (FPG) and glycated hemoglobin A1c (HbA1c) [126]. However, in a 3-year prospective study of high-risk individuals OC did not predict diabetes [127] and in a nested case-control study monitoring the risk of type 2 diabetes over a 10-year follow-up OC and ucOC were not associated with increased risk of type 2 diabetes [128].

## Other Diseases

In addition to the aforementioned areas, vitamin K has been suggested to be involved in other diseases. One of these is osteoarthritis where elevated levels of dp-ucMGP have been associated with presence of osteophytes, meniscal damage and subcondral cysts, but not with progression of the disease [129]. Subjects in this study with low plasma vitamin K<sub>1</sub> were more likely to have progression of articular cartilage damage. Genome-wide association and functional studies with low expression of MGP are linked to an increased risk for hand osteoarthritis [130]. Other studies have identified vitamin K deficiency as a risk factor for osteoarthritis and have suggested supplementation studies to evaluate the effect of vitamin K on osteoarthritis [131,132]. To date only one such study has been published. In that study subjects received vitamin K<sub>1</sub> supplementation during three years and hand x-rays were performed at baseline and after the supplementation period. No effect of vitamin K<sub>1</sub> supplementation was seen [133]. Possible reasons include insufficient doses and observation period, underpowered study or wrong vitamin K subspecies as vitamin K<sub>2</sub> has a better bioavailability for extra-hepatic Gla proteins. Another research area where vitamin K supplementation has been suggested is neurodegenerative diseases such as Alzheimer's disease. Possible mechanisms of action involving sphingolipid metabolism, Gas6-mediated Axl stimulation and apolipoprotein E

genotypes are discussed in a previously published review article [134]. Furthermore, vitamin K<sub>3</sub> analogues have demonstrated inhibition of Aβ aggregation *in vitro* and *in silico*, and might be potential anti-amyloidogenic drug targets [135]. Another possible area of application for vitamin K<sub>3</sub> is as an antimicrobial agent as *in vitro* studies have demonstrated growth inhibition and decreased exotoxin production in both gram-positive and gram-negative bacteria exposed to vitamin K<sub>3</sub> [136]. An additional antimicrobial strategy, could be inhibition of menaquinone biosynthesis, as several bacteria require menaquinones for their respiratory chain. *In vitro* studies have demonstrated that inhibition of menaquinone synthesis resulted in inhibition of both replicating and non-replicating as well as drug-resistant strains of *Mycobacterium tuberculosis* [137].

## Conclusions

During the past decades evidence that vitamin K is involved in areas extending far beyond hemostasis has accumulated. Several mechanisms of action involving both direct interaction via receptors such as the SXR and indirect via post-translational modification of Gla proteins have been proposed. The metabolism of vitamin K is complex and has large interspecies variation. Furthermore, limited knowledge about bioavailability and the lack of a gold standard biomarker complicate creating optimal vitamin K intake guidelines for different populations.

Pre-clinical studies have suggested involvement of vitamin K and Gla proteins in cardiovascular disease, diabetes, osteoporosis and cancer, which has motivated several clinical trials evaluating the effect of supplementation with different forms of vitamin K. In general, the bulk of the trials considered in this review comprise a small number of subjects making it hard to draw definitive conclusions. The involvement of vitamin K and MGP in cardiovascular disease is among the most extensively studied and the limited number of completed studies shows promising results for the vitamin K<sub>2</sub> form MK-7. Larger, well-designed trials are ongoing and results are expected within the next few years. Studies on whether vitamin K supplementation is beneficial for patients with osteoporosis have shown reduced fracture incidence and improved bone health in patients with advanced disease. The least explored area in terms of clinical trials is whether vitamin K can be used in cancer therapy. MK-4 was initially reported to have anti-tumour effects on HCC, but this was not confirmed in a recent systematic review. Vitamin K<sub>3</sub> produces ROS which have been utilized in clinical trials but not enough data exist on this issue. The involvement of vitamin K in metabolic disease has been investigated after large population studies suggested an inverse relationship between vitamin K intake and type 2 diabetes, but so far results have been inconclusive. The latest debated topic is whether uncarboxylated OC affects glucose homeostasis, but no consensus has been reached and studies show conflicting results.

In conclusion, clinical trials indicate that supplementation with vitamin K has beneficial effects on various diseases with the most compelling evidence for cardiovascular disease.

**Acknowledgments:** This review was funded by University of Lund ISEX-ALF (Sweden).

**Author Contributions:** All authors listed have contributed to the Work; all authors have read, approved and agreed to submit the manuscript to Nutrition and Metabolism: An Open Access.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

- Willems BA, Vermeer C, Reutelingsperger CP, Schurgers LJ (2014) The realm of vitamin K dependent proteins: Shifting from coagulation toward calcification. *Mol Nutr Food Res* 58: 1620-1635.
- Liabeuf S, Bourron O, Vermeer C, Theuvsen E, Magdeleyns E, et al. (2014) Vascular calcification in patients with type 2 diabetes: The involvement of matrix gla protein. *Cardiovasc Diabetol* 13: 85.
- Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, et al. (2014) Dephosphorylated-uncarboxylated matrix gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. *BMC Nephrol* 15: 145.
- Mayer O Jr, Seidlerova J, Bruthans J, Filipovsky J, Timoracka K, et al. (2014) Dephospho-uncarboxylated matrix gla-protein is associated with mortality risk in patients with chronic stable vascular disease. *Atherosclerosis* 235: 162-168.
- Viegas CS, Rafael MS, Enriquez JL, Teixeira A, Vitorino R, et al. (2015) Gla-rich protein acts as a calcification inhibitor in the human cardiovascular system. *Arterioscler Thromb Vasc Biol* 35: 399-408.
- Neve A, Corrado A, Cantatore FP (2013) Osteocalcin: Skeletal and extra-skeletal effects. *J Cell Physiol* 228: 1149-1153.
- Wu G, Ma Z, Hu W, Wang D, Gong B, et al. (2017) Molecular insights of Gas6/TAM in cancer development and therapy. *Cell Death Dis* 8: e2700.
- Nimptsch K, Rohrmann S, Kaaks R, Linseisen J (2010) Dietary vitamin K intake in relation to cancer incidence and mortality: Results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). *Am J Clin Nutr* 91: 1348-1358.
- Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, et al. (2004) Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: The rotterdam study. *J Nutr* 134: 3100-3105.
- Knapen MH, Braam LA, Teunissen KJ, Zwijsen RM, Theuvsen E, et al. (2015) Yogurt drink fortified with menaquinone-7 improves vitamin K status in a healthy population. *J Nutr Sci* 4: e35.
- Eisenreich W, Bacher A, Arigoni D, Rohdich F (2004) Biosynthesis of isoprenoids via the non-mevalonate pathway. *Cell Mol Life Sci* 61: 1401-1426.
- Shearer MJ (1995) Vitamin K. *Lancet* 345: 229-234.
- Oostende CV, Widhalm JR, Basset GJ (2008) Detection and quantification of vitamin K (1) quinol in leaf tissues. *Phytochemistry* 69: 2457-2462.
- Nowicka B, Kruk J (2010) Occurrence, biosynthesis and function of isoprenoid quinones. *Biochim Biophys Acta* 1797: 1587-1605.
- Elder SJ, Haytowitz DB, Howe J, Peterson JW, Booth SL (2006) Vitamin K contents of meat, dairy, and fast food in the U.S. *Diet. J Agric Food Chem* 54: 463-467.
- Suhara Y, Watanabe M, Motoyoshi S, Nakagawa K., Wada A, et al. (2011) Synthesis of new vitamin K analogues as steroid and xenobiotic receptor (SXR) agonists: Insights into the biological role of the side chain part of vitamin K. *J Med Chem* 54: 4918-4922.
- Shearer MJ, Newman P (2008) Metabolism and cell biology of vitamin K. *Thromb Haemost* 100: 530-547.
- Martius C (1961) The metabolic relationships between the different K vitamins and the synthesis of the ubiquinones. *Am J Clin Nutr* 2: 97-103.
- Thijssen HH, Vervoort LM, Schurgers LJ, Shearer MJ (2006) Menadi-one is a metabolite of oral vitamin K. *Br J Nutr* 95: 260-266.
- Okano T, Shimomura Y, Yamane M, Suhara Y, Kamao M, et al. (2008) Conversion of phyloquinone (vitamin K1) into menaquinone-4 (vitamin K2) in mice: Two possible routes for menaquinone-4 accumulation in cerebra of mice. *J Biol Chem* 283: 11270-11279.
- Nakagawa K, Hirota Y, Sawada N, Yuge N, Watanabe M, et al. (2010) Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. *Nature* 468: 117-121.
- Chen Z, Qureshi AR, Parini P, Hurt-Camejo E, Ripsweiden J, et al. (2017) Does statins promote vascular calcification in chronic kidney disease? *Eur J Clin Invest* 47: 137-148.
- Parker CH, Morgan CR, Rand KD, Engen JR, Jorgenson JW, et al. (2014) A conformational investigation of propeptide binding to the integral membrane protein gamma-glutamyl carboxylase using nanodisc hydrogen exchange mass spectrometry. *Biochemistry* 53: 1511-1520.
- Stanley TB, Jin DY, Lin PJ, Stafford DW (1999) The propeptides of the vitamin K-dependent proteins possess different affinities for the vitamin K-dependent carboxylase. *J Biol Chem* 274: 16940-16944.
- Tie JK, Stafford DW (2016) Structural and functional insights into enzymes of the vitamin K cycle. *J ThrombHaemost* 14: 236-247.
- Wajih N, Hutson SM, Wallin R (2007) Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction. *J Biol Chem* 282: 2626-2635.
- Schulman S, Wang B, Li W, Rapoport TA (2010) Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners. *Proc Natl Acad Sci U S A* 107: 15027-15032.
- Wajih N, Sane DC, Hutson SM, Wallin R (2004) The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. *J Biol Chem* 279: 25276-25283.

29. Wajih N, Hutson SM, Wallin R (2006) siRNA silencing of calumenin enhances functional factor IX production. *Blood* 108: 3757-3760.
30. Wajih N, Hutson SM, Owen J, Wallin R (2005) Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle. *J Biol Chem* 280: 31603-31607.
31. Stenflo J, Fernlund P, Egan W, Roepstorff P (1974) Vitamin K dependent modifications of glutamic acid residues in prothrombin. *Proc Natl Acad Sci U S A* 71: 2730-2733.
32. Hauschka PV, Lian JB, Gallop PM (1975) Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. *Proc Natl Acad Sci U S A* 72: 3925-3929.
33. Wei J, Karsenty G (2015) An overview of the metabolic functions of osteocalcin. *Rev Endocr Metab Disord* 16: 93-98.
34. Wei J, Hanna T, Suda N, Karsenty G, Ducy P (2014) Osteocalcin promotes beta-cell proliferation during development and adulthood through Gprc6a. *Diabetes* 63: 1021-1031.
35. Price PA, Urist MR, Otawara Y (1983) Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. *Biochem Biophys Res Commun* 117: 765-771.
36. Schurgers LJ, Cranenburg EC, Vermeer C (2008) Matrix Gla-protein: The calcification inhibitor in need of vitamin K. *Thromb Haemostasis* 100: 593-603.
37. Riphagen IJ, Keyzer CA, Drummen NEA, de Borst MH, Beulens JWW, et al. (2017) Prevalence and effects of functional vitamin K deficiency: The prevent study. *Nutrients* 9.
38. Caluwe R, Pyfferoen L, De Boeck K., De Vriese AS (2016) The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: Ongoing randomized controlled trials. *Clin Kidney J* 9: 273-279.
39. Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM (2018) Role of smooth muscle cells in vascular calcification: Implications in atherosclerosis and arterial stiffness. *Cardiovasc Res* 114: 590-600.
40. Schurgers LJ, Teunissen K.J, Knapen MH, Kwaijtaal M, van Diest R, et al. (2005) Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: Undercarboxylated matrix Gla protein as marker for vascular calcification. *Arterioscler Thromb Vasc Biol* 25: 1629-1633.
41. van der Meer JH, van der Poll T, van 't Veer C (2014) TAM receptors, Gas6, and protein S: Roles in inflammation and hemostasis. *Blood* 123: 2460-2469.
42. Fouad NA, Eltaher SM, Abdullah OA, Metwally RA (2015) Serum level of growth arrest-specific 6 (Gas6) protein and genetic variations in the Gas6 gene in patients with type 2 diabetes mellitus. *Egypt J Immunol* 22: 41-47.
43. Hung YJ, Lee CH, Chu NF, Shieh YS (2010) Plasma protein growth arrest-specific 6 levels are associated with altered glucose tolerance, inflammation, and endothelial dysfunction. *Diabetes Care* 33: 1840-1844.
44. Nakano T, Kawamoto K., Kishino J, Nomura K, Higashino K, et al. (1997) Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. *Biochem J* 323: 387-392.
45. Bolton-Smith C, Price RJ, Fenton ST, Harrington DJ, Shearer MJ (2000) Compilation of a provisional UK database for the phyloquinone (vitamin K1) content of foods. *Br J Nutr* 83: 389-399.
46. Manoury E, Jourdon K, Boyaval P, Fourcassie P (2013) Quantitative measurement of vitamin K2 (menaquinones) in various fermented dairy products using a reliable high-performance liquid chromatography method. *J Dairy Sci* 96: 1335-1346.
47. Homma K, Wakana N, Suzuki Y, Nukui M, Daimatsu T, et al. (2006) Treatment of natto, a fermented soybean preparation, to prevent excessive plasma vitamin K concentrations in patients taking warfarin. *J Nutr Sci Vitaminol (Tokyo)* 52: 297-301.
48. Schurgers L, Vermeer C (2000) Determination of phyloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. *Haemostasis* 30: 298-307.
49. Fu X, Shen X, Finnan EG, Haytowitz DB, Booth SL (2016) Measurement of multiple vitamin K forms in processed and fresh-cut pork products in the U.S. Food supply. *J Agric Food Chem* 64: 4531-4535.
50. Rasekhi H, Karandish M, Jalali MT, Mohammad-Shahi M, Zarei M, et al. (2015) The effect of vitamin K1 supplementation on sensitivity and insulin resistance via osteocalcin in prediabetic women: A double-blind randomized controlled clinical trial. *Eur J Clin Nutr* 69: 891-895.
51. Yoshida M, Jacques PF, Meigs JB, Saltzman E, Shea MK, et al. (2008) Effect of vitamin K supplementation on insulin resistance in older men and women. *Diabetes Care* 31: 2092-2096.
52. Huang ZB, Wan SL, Lu YJ, Ning L, Liu C, et al. (2015) Does vitamin K2 play a role in the prevention and treatment of osteoporosis for postmenopausal women: A meta-analysis of randomized controlled trials. *Osteoporos Int* 26: 1175-1186.
53. Mansour AG, Hariri E, Daaboul Y, Korjian S, El Alam A, et al. (2017) Vitamin K2 supplementation and arterial stiffness among renal transplant recipients—a single-arm, single-center clinical trial. *J Am Soc Hypertens* 11: 589-597.
54. He T, Hatem E, Vernis L, Lei M, Huang ME (2015) PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: A potential new therapeutic perspective for an old drug. *J Exp Clin Cancer Res* 34: 152.
55. Tareen B, Summers JL, Jamison JM, Neal DR, McGuire K, et al. (2008) A 12-week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy. *Int J Med Sci* 5: 62-67.
56. Lipsky JJ (1988) Antibiotic-associated hypoprothrombinaemia. *J Antimicrob Chemother* 21: 281-300.
57. Suttie JW (1995) The importance of menaquinones in human nutrition. *Annu Rev Nutr* 15: 399-417.
58. Gijsbers BL, Jie KS, Vermeer C (1996) Effect of food composition on vitamin K absorption in human volunteers. *Br J Nutr* 76: 223-229.
59. Booth SL, Lichtenstein AH, Dallal GE (2002) Phyloquinone absorption from phyloquinone-fortified oil is greater than from a vegetable in younger and older men and women. *J Nutr* 132: 2609-2612.
60. Erkkila AT, Lichtenstein AH, Dolnikowski GG, Grusak MA, Jalbert SM, et al. (2004) Plasma transport of vitamin K in men using deuterium-labeled collard greens. *Metabolism* 53: 215-221.



61. Schurgers LJ, Vermeer C (2002) Differential lipoprotein transport pathways of K-vitamins in healthy subjects. *Biochim Biophys Acta* 1570: 27-32.
62. Schurgers LJ, Teunissen KJ, Hamulyak K, Knapen MH, Vik H, et al. (2007) Vitamin K-containing dietary supplements: Comparison of synthetic vitamin K1 and natto-derived menaquinone-7. *Blood* 109: 3279-3283.
63. Kohlmeier M, Salomon A, Saupe J, Shearer MJ (1996) Transport of vitamin K to bone in humans. *J Nutr* 126: 1192-1196.
64. Craciun AM, Vermeer C (2013) Apolipoprotein E genotype may influence urinary gamma-carboxyglutamate (Gla) concentrations in young individuals. *Gen Physiol Biophys* 32: 303-310.
65. Dauti F, Hjaltalin Jonsson M, Hillarp A, Bentzer P, Schott U (2015) Peri-operative changes in PIVKA-II. *Scand J Clin Lab Invest* 75: 562-567.
66. Dahlberg S, Nilsson CU, Kander T, Schott U (2017) Detection of sub-clinical vitamin K deficiency in neurosurgery with PIVKA-II. *Scand J Clin Lab Invest* 77: 267-274.
67. Theuwissen E, Magdeleyns EJ, Braam LA, Teunissen KJ, Knapen MH, et al. (2014) Vitamin K status in healthy volunteers. *Food Funct* 5: 229-234.
68. Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, et al. (2001) Low serum and bone vitamin K status in patients with long-standing Crohn's disease: Another pathogenetic factor of osteoporosis in Crohn's disease? *Gut* 48: 473-477.
69. Strole J, Lovell G, Heubi J (2009) Prevalence of subclinical vitamin K deficiency in cholestatic liver disease. *J Pediatr Gastroenterol Nutr* 49: 78-84.
70. Kaesler N, Magdeleyns E, Herfs M, Schettgen T, Brandenburg V, et al. (2014) Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. *Kidney Int* 86: 286-293.
71. McCabe KM, Adams MA, Holden RM (2013) Vitamin K status in chronic kidney disease. *Nutrients* 5: 4390-4398.
72. Booth SL, Pennington JA, Sadowski JA (1996) Dihydro-vitamin K1: Primary food sources and estimated dietary intakes in the american diet. *Lipids* 31: 715-720.
73. Sato T, Ozaki R, Kamo S, Hara Y, Konishi S, et al. (2003) The biological activity and tissue distribution of 2',3'-dihydrophyloquinone in rats. *Biochimica et biophysica acta* 1622: 145-150.
74. Booth SL, Peterson JW, Smith D, Shea MK, Chamberland J, et al. (2008) Age and dietary form of vitamin K affect menaquinone-4 concentrations in male fischer 344 rats. *J Nutr* 138: 492-496.
75. Allen K, Pearson-Stuttard J, Hooton W, Diggle P, Capewell S, et al. (2015) Potential of trans fats policies to reduce socioeconomic inequalities in mortality from coronary heart disease in England: Cost effectiveness modelling study. *BMJ* 351: h4583.
76. Mandelbrot L, Guillaumont M, Leclercq M, Lefrere JJ, Gozin D, et al. (1988) Placental transfer of vitamin K1 and its implications in fetal hemostasis. *Thromb Haemost* 60: 39-43.
77. Lane PA, Hathaway WE (1985) Vitamin K in infancy. *The Journal of Pediatrics* 106: 351-359.
78. Aballi AJ, De Lamerens S (1962) Coagulation changes in the neonatal period and in early infancy. *Pediatr Clin North Am* 9: 785-817.
79. von Kries R, Becker A, Gobel U (1987) Vitamin K in the newborn: Influence of nutritional factors on a carboxy-prothrombin detectability and factor II and VII clotting activity. *Eur J Pediatr* 146: 123-127.
80. Dam H, Dyggve H, Larsen H, Plum P (1952) The relation of vitamin K deficiency to hemorrhagic disease of the newborn. *Adv Pediatr* 5: 129-153.
81. Meyer TC, Angus J (1956) The effect of large doses of synkavit in the newborn. *Arch Dis Child* 31: 212-215.
82. (1961) Vitamin K compounds and the water-soluble analogues. Use in therapy and prophylaxis in pediatrics. *Pediatrics* 28: 501-507.
83. Sharma RK, Marwaha N, Kumar P, Narang A (1995) Effect of oral water-soluble vitamin K on PIVKA-II levels in newborns. *Indian Pediatr* 32: 863-867.
84. Shearer MJ (2009) Vitamin K deficiency bleeding (VKDB) in early infancy. *Blood Rev* 23: 49-59.
85. Golding J, Paterson M, Kinlen LJ (1990) Factors associated with childhood cancer in a national cohort study. *Br J Cancer* 62: 304-308.
86. Roman E, Fear NT, Ansell P, Bull D, Draper G, et al. (2002) Vitamin K and childhood cancer: Analysis of individual patient data from six case-control studies. *Br J Cancer* 86: 63-69.
87. Fear NT, Roman E, Ansell P, Simpson J, Day N, et al. (2003) Vitamin K and childhood cancer: A report from the United Kingdom Childhood Cancer Study. *Br J Cancer* 89: 1228-1231.
88. Lerner RG, Aronow WS, Sekhri A, Palaniswamy C, Ahn C, et al. (2009) Warfarin use and the risk of valvular calcification. *J Thromb Haemost* 7: 2023-2027.
89. Mac-Way F, Poulin A, Utescu MS, De Serres SA, Marquis K, et al. (2014) The impact of warfarin on the rate of progression of aortic stiffness in hemodialysis patients: A longitudinal study. *Nephrol Dial Transplant* 29: 2113-2120.
90. Frick PG, Riedler G, Brogli H (1967) Dose response and minimal daily requirement for vitamin K in man. *J Appl Physiol* 23: 387-389.
91. Shearer MJ, Fu X, Booth SL (2012) Vitamin K nutrition, metabolism, and requirements: Current concepts and future research. *Adv Nutr* 3: 182-195.
92. Leaf AA (2007) Vitamins for babies and young children. *Arch Dis Child* 92: 160-164.
93. Vermeer C, Shearer MJ, Zittermann A, Bolton-Smith C, Szulc P, et al. (2004) Beyond deficiency: Potential benefits of increased intakes of vitamin K for bone and vascular health. *Eur J Nutr* 43: 325-335.
94. Beulens JW, Booth SL, van den Heuvel EG, Stoecklin E, Baka A, et al. (2013) The role of menaquinones (vitamin K (2)) in human health. *Br J Nutr* 110: 1357-1368.
95. Fusaro M, Gallieni M, Rizzo MA, Stucchi A, Delanaye P, et al. (2017) Vitamin K plasma levels determination in human health. *Clin Chem Lab Med* 55: 789-799.
96. Riphagen IJ, van der Molen JC, van Faassen M, Navis G, de Borst MH, et al. (2016) Measurement of plasma vitamin K1 (phyloquinone) and K2 (menaquinones-4 and -7) using HPLC-tandem mass spectrometry. *Clin Chem Lab Med* 54: 1201-1210.



97. Shea MK, Booth SL (2016) Concepts and controversies in evaluating vitamin K status in population-based studies. *Nutrients* 8.
98. Gajic-Veljanoski O, Bayoumi AM, Tomlinson G, Khan K, Cheung AM (2012) Vitamin K supplementation for the primary prevention of osteoporotic fractures: Is it cost-effective and is future research warranted? *Osteoporos Int* 23: 2681-2692.
99. Berenjian A, Mahanama R, Kavanagh J, Dehghani F (2015) Vitamin K series: Current status and future prospects. *Crit Rev Biotechnol* 35: 199-208.
100. Braam LA, Hoeks AP, Brouns F, Hamulyak K, Gerichhausen MJ, et al. (2004) Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: A follow-up study. *Thromb Haemost* 91: 373-380.
101. Shea MK, O'Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, et al. (2009) Vitamin K supplementation and progression of coronary artery calcium in older men and women. *Am J Clin Nutr* 89: 1799-1807.
102. Fulton RL, McMurdo ME, Hill A, Abboud RJ, Arnold GP, et al. (2016) Effect of vitamin K on vascular health and physical function in older people with vascular disease--a randomised controlled trial. *J Nutr Health Aging* 20: 325-333.
103. Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, et al. (2014) Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): A rationale and study protocol. *Nephrol Dial Transplant* 29: 1633-1638.
104. Holden RM, Booth SL, Day AG, Clase CM, Zimmerman D, et al. (2015) Inhibiting the progression of arterial calcification with vitamin K in hemodialysis patients (iPACK-HD) trial: Rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. *Can J Kidney Health Dis* 2: 17.
105. Caluwe R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS (2014) Vitamin K2 supplementation in haemodialysis patients: A randomized dose-finding study. *Nephrol Dial Transplant* 29: 1385-1390.
106. Aoun M, Makki M, Azar H, Matta H, Chelala DN (2017) High dephosphorylated-uncarboxylated MGP in hemodialysis patients: Risk factors and response to vitamin K2, a pre-post intervention clinical trial. *BMC Nephrol* 18: 191.
107. Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, et al. (2015) Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. *Thromb Haemost* 113: 1135-1144.
108. Vossen LM, Schurgers LJ, van Varik BJ, Kietselaer BL, Vermeer C, et al. (2015) Menaquinone-7 supplementation to reduce vascular calcification in patients with coronary artery disease: Rationale and study protocol (VitaK-CACTrial). *Nutrients* 7: 8905-8915.
109. Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, et al. (2012) Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. *Am J Kidney Dis* 59: 186-195.
110. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, et al. (2006) Vitamin K and the prevention of fractures: Systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med* 166: 1256-1261.
111. Iwamoto J, Sato Y, Takeda T, Matsumoto H (2009) High-dose vitamin K supplementation reduces fracture incidence in postmenopausal women: A review of the literature. *Nutr Res* 29: 221-228.
112. Inoue T, Fujita T, Kishimoto H, Makino T, Nakamura T, et al. (2009) Randomized controlled study on the prevention of osteoporotic fractures (OF study): A phase IV clinical study of 15-mg menatetrenone capsules. *J Bone Miner Metab* 27: 66-75.
113. Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, et al. (2014) Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). *J Bone Miner Metab* 32: 298-304.
114. Lamson DW, Plaza SM (2003) The anticancer effects of vitamin K. *Altern Med Rev* 8: 303-318.
115. Juanola-Falgarona M, Salas-Salvado J, Martinez-Gonzalez MA, Corella D, Estruch R, et al. (2014) Dietary intake of vitamin K is inversely associated with mortality risk. *J Nutr* 144: 743-750.
116. Riaz IB, Riaz H, Riaz T, Rahman S, Amir M, et al. (2012) Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: A meta-analysis of randomized controlled trials. *BMC Gastroenterol* 12: 170.
117. Wu J, Chien CC, Yang LY, Huang GC, Cheng MC, et al. (2011) Vitamin K3-2,3-epoxide induction of apoptosis with activation of ROS-dependent ERK and JNK protein phosphorylation in human glioma cells. *Chem Biol Interact* 193: 3-11.
118. Beulens JW, van der AD, Grobbee DE, Sluijs I, Spijkerman AM, et al. (2010) Dietary phyloquinone and menaquinones intakes and risk of type 2 diabetes. *Diabetes Care* 33: 1699-1705.
119. Ibarrola-Jurado N, Salas-Salvado J, Martinez-Gonzalez MA, Bullo M (2012) Dietary phyloquinone intake and risk of type 2 diabetes in elderly subjects at high risk of cardiovascular disease. *Am J Clin Nutr* 96: 1113-1118.
120. Pan Y, Jackson RT (2009) Dietary phyloquinone intakes and metabolic syndrome in US young adults. *J Am Coll Nutr* 28: 369-379.
121. Dam V, Dalmeijer GW, Vermeer C, Drummen NE, Knapen MH, et al. (2015) Association between vitamin K and the metabolic syndrome: A 10-year follow-up study in adults. *J Clin Endocrinol Metab* 100: 2472-2479.
122. Suksomboon N, Poolsup N, Darli KoKo H (2017) Effect of vitamin K supplementation on insulin sensitivity: A meta-analysis. *Diabetes Metab Syndr Obes* 10: 169-177.
123. Korostishevsky M, Malkin I, Trofimov S, Pei Y, Deng HW, et al. (2012) Significant association between body composition phenotypes and the osteocalcin genomic region in normative human population. *Bone* 51: 688-694.
124. Liu C, Wo J, Zhao Q, Wang Y, Wang B, et al. (2015) Association between serum total osteocalcin level and type 2 diabetes mellitus: A systematic review and meta-analysis. *Horm Metab Res* 47: 813-819.
125. Kunutsor SK, Apekey TA, Laukkanen JA (2015) Association of serum total osteocalcin with type 2 diabetes and intermediate metabolic phenotypes: Systematic review and meta-analysis of observational evidence. *Eur J Epidemiol* 30: 599-614.

126. Liu DM, Guo XZ, Tong HJ, Tao B, Sun LH, et al. (2015) Association between osteocalcin and glucose metabolism: A meta-analysis. *Osteoporos Int* 26: 2823-2833.
127. Liatis S, Sfrikakis PP, Tsiakou A, Stathi C, Terpos E, et al. (2014) Baseline osteocalcin levels and incident diabetes in a 3-year prospective study of high-risk individuals. *Diabetes Metab* 40: 198-203.
128. Zwakenberg SR, Gundberg CM, Spijkerman AM, van der AD, van der Schouw YT, et al. (2015) Osteocalcin is not associated with the risk of type 2 diabetes: Findings from the EPIC-NL study. *PLoS One* 10: e0138693.
129. Shea MK, Kritchevsky SB, Hsu FC, Nevitt M, Booth SL, et al. (2015) The association between vitamin K status and knee osteoarthritis features in older adults: The health, aging and body composition study. *Osteoarthritis Cartilage* 23: 370-378.
130. den Hollander W, Boer CG, Hart DJ, Yau MS, Ramos YFM, et al. (2017) Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand. *Ann Rheum Dis* 76: 2046-2053.
131. Oka H, Akune T, Muraki S, En-yo Y, Yoshida M, et al. (2009) Association of low dietary vitamin K intake with radiographic knee osteoarthritis in the Japanese elderly population: Dietary survey in a population-based cohort of the ROAD study. *J Orthop Sci* 14: 687-692.
132. Misra D, Booth SL, Tolstykh I, Felson DT, Nevitt MC, et al. (2013) Vitamin K deficiency is associated with incident knee osteoarthritis. *Am J Med* 126: 243-248.
133. Neogi T, Felson DT, Sarno R, Booth SL (2008) Vitamin K in hand osteoarthritis: Results from a randomised clinical trial. *Ann Rheum Dis* 67: 1570-1573.
134. Allison AC (2001) The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease. *Med Hypotheses* 57: 151-155.
135. Huy PD, Yu YC, Ngo ST, Thao TV, Chen CP, et al. (2013) *In silico* and *in vitro* characterization of anti-amyloidogenic activity of vitamin K3 analogues for Alzheimer's disease. *Biochim Biophys Acta* 1830: 2960-2969.
136. Schlievert PM, Merriman JA, Salgado-Pabon W, Mueller EA, Spaulding AR, et al. (2013) Menaquinone analogs inhibit growth of bacterial pathogens. *Antimicrob Agents Chemother* 57: 5432-5437.
137. Sukheja P, Kumar P, Mittal N, Li SG, Singleton E, et al. (2017) A novel small-molecule inhibitor of the *Mycobacterium tuberculosis* Demethylmenaquinone Methyltransferase MenG is bactericidal to both growing and nutritionally deprived persister cells. *MBio* 8:e02022-16